Another treatment option for locally advanced hepatocellular carcinoma: Interventional arterial infusion of FOLFOX chemotherapy from the FOHAIC-1 study
Advanced stage primary hepatocellular carcinoma (HCC) accounts for more than half of all cases worldwide. Poor prognosis is mainly attributed to intrahepatic tumor burden caused by high-risk factors, including Vp4-portal vein tumor thrombosis or tumor occupancy of >50% of the liver. In 2020, the...
Main Authors: | Lyu Ning, Zhao Ming |
---|---|
Format: | Article |
Language: | English |
Published: |
EDP Sciences
2022-01-01
|
Series: | Visualized Cancer Medicine |
Subjects: | |
Online Access: | https://vcm.edpsciences.org/articles/vcm/full_html/2022/01/vcm20220002/vcm20220002.html |
Similar Items
-
Efficacy and safety of atezolizumab plus bevacizumab combined with hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma
by: Yujing Xin, et al.
Published: (2022-08-01) -
Hepatic artery infusion chemotherapy using mFOLFOX versus transarterial chemoembolization for massive unresectable hepatocellular carcinoma: a prospective non-randomized study
by: Min-Ke He, et al.
Published: (2017-10-01) -
Hepatic arterial infusion chemotherapy in hepatocellular carcinoma: A bibliometric and knowledge-map analysis
by: Mei Li, et al.
Published: (2023-01-01) -
Cost-Effectiveness Analysis of Hepatic Arterial Infusion of FOLFOX Combined Sorafenib for Advanced Hepatocellular Carcinoma With Portal Vein Invasion
by: Meiyue Li, et al.
Published: (2021-03-01) -
Cost-effectiveness analysis of FOLFOX4 and sorafenib for the treatment of advanced hepatocellular carcinoma in China
by: Shukui Qin, et al.
Published: (2018-08-01)